Beyond Market Access – Foundations for Sustaining Europe’s IVD Leadership
Europe’s diagnostics industry shows visible continuity but declining structural durability. IVD’s share of healthcare expenditure fell from 0.80% in 2009 to 0.60% in 2023. Real growth is weak. Capital duration is stressed. Regulatory and evidence obligations fall disproportionately on smaller suppliers. Five structural gaps—competitiveness, fixed-burden absorption, value capture, scale-up and industrial plurality—remain beyond market access alone. Measurement frameworks capture only half the industry, weakening visibility and policy debate.
Published May 2026
Miguel Oliveira
IVD Industry Monograph No. 3 — Persodia Research
Why Does This Matter Now?
Europe’s in-vitro diagnostics industry serves not only European healthcare systems but global ones. European Union manufacturing output is approximately USD 49 billion annually, against approximately USD 33 billion of regional market demand.
Visible continuity, however, should not be confused with structural durability. Products remain available. Laboratories operate. Major manufacturers continue to serve the market. The relevant question is not whether European diagnostics is functioning today. It is whether the industrial conditions that make that position durable over time are receiving proportionate reinforcement as the expectations placed on diagnostics expand.
The Central Finding
Five signs point to conditions beneath visible market continuity that deserve closer attention:
- The IVD market’s share of total European healthcare expenditure declined monotonically from 0.80 percent in 2009 to 0.60 percent in 2023: every anchor year, without interruption.
- Real IVD growth over the 2014–2023 reference period was approximately –0.13 percent annually on a reported basis.
- Diagnostic use is rising while supplier revenue capture remains constrained.
- Capital takes longer to return as institutional gates multiply.
- Regulatory, digital and evidence obligations fall proportionally harder on smaller suppliers: the companies that carry much of the industry’s renewal and plurality potential.
One finding cuts across all five. The industry cannot make its case coherently because it cannot fully measure itself. The established reporting framework captures less than half of the complete European diagnostics economy. A framework that records only part of the industry’s economic scale weakens the visibility of its contribution and limits the quality of the debate around its future.
What This Monograph Examines
The monograph is organised around four questions, examined through five structural lenses.
Chapter 1 — Europe’s Diagnostics Capacity
What diagnostic capacity does Europe actually have?
This chapter examines population health need, diagnostic-access infrastructure across the patient journey, the definition and scope of the European IVD industry, Europe’s position in the global IVD market, and the European manufacturer base and trade position.
Chapter 2 — Five Societal Expectations for Diagnostics
What is healthcare now expecting from diagnostics?
This chapter covers earlier and more accurate clinical decisions, more efficient healthcare delivery, precision medicine and innovative care, system resilience and public-health readiness, and digital, regulatory and evidence infrastructure.
Chapter 3 — Five Signs of Insufficient Reinforcement
Where are the signs that reinforcement may be insufficient?
This chapter examines declining participation in healthcare expenditure, weak real reinforcement, diagnostic use growing faster than supplier revenue, capital-duration stress and participation-burden asymmetry.
Chapter 4 — Five Structural Gaps Beyond Market Access
What structural gaps remain beyond the reach of market access alone?
This chapter addresses competitiveness and procurement, fixed-burden absorption, value capture and investment returns, scale-up and market entry, and industrial plurality and resilience.
Each chapter reads in under ten minutes. The argument builds across all four, but every section stands on its own.
Field Observation
The analytical framework was tested against field observation at MedTech Forum Stockholm 2026. The same diagnosis surfaced repeatedly across formal sessions, corridor conversations and closed-door exchanges: executives, policymakers, investors and clinical leaders arrived from different directions and converged on the same concern. The monograph was substantially shaped by what was heard there.
Analytical Basis
The monograph applies the structural framework developed in Inside the Clinical Diagnostics Industry: Constraints Shaping Strategy — Towards Health Intelligence to the specific question of European IVD industrial sustainability.
It draws on Persodia Research market studies, public institutional sources including Eurostat System of Health Accounts data, MedTech Europe market statistics, and professional observation at MedTech Forum Stockholm 2026, ESCMID Global Munich 2026 and Analytica Munich 2026.
This is the third publication in the IVD Industry Monograph series: the primary analytical output of Persodia Research.
Strategic Implications
Europe’s diagnostics position should not be assessed solely through visible market continuity.
For industry executives, the relevant issues are capital duration, fixed-burden absorption and the ability to sustain innovation under increasing institutional obligations.
For policymakers and industry bodies, the immediate priority is more complete measurement. A sector that captures only part of its economic scale in established reporting frameworks cannot represent its contribution adequately or frame the debate around its future with sufficient precision.
For investors, the relevant issue is not simply market size. It is whether the conditions governing value capture, scale-up and durable returns remain proportionate to the obligations placed on suppliers.
Related Persodia Material
About the Series
Each monograph in the IVD Industry Monograph series examines a single structural question at the intersection of industry organisation, clinical deployment and market economics.
The series is observational rather than prescriptive, cumulative rather than episodic.
Assumed Knowledge
The monograph assumes familiarity with the IVD industry and with the institutional conditions of European healthcare markets.
Readers without direct commercial or technical experience in the sector will find the structural argument accessible but will benefit from prior reading of Inside the Clinical Diagnostics Industry.
Access
This monograph is available without charge.
Access requires a brief declaration of context and intended use. Persodia Research wishes to understand who engages with the material and in what professional context.
Full copyright is retained by the author. The material may be read, cited and discussed freely. It may not be reproduced or repurposed without prior written permission.
Request Download
IVD Industry Monograph No. 3
Enter your details below. A secure, single-use link will be sent to your email address. The link can be used once and does not expire.